Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?

AJ Thompson; JG Mchutchison

Journal article

Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?

AJ Thompson, JG Mchutchison

Hepatology | WILEY | Published : 2012

DOI: 10.1002/hep.25792

University of Melbourne Researchers

Alexander Thompson Author

Related Projects (1)

Genetic determinants of clinical outcome and treatment response in chronic hepatitis C

Chronic hepatitis C infection (CHC) causes liver failure, liver cancer and death. The treatment response rate is poor. Understanding of the ..

Grants

Funding Acknowledgements

A.J.T and J.G.M are coinventors of a patent related to the IL28B discovery. A.J.T has received research support from Merck, Roche and Gilead Sciences, has served as a consultant for Merck, Roche and Janssen-Cilag, and has served on speaker bureaus for Merck. J.G.M. is an employee of Gilead Sciences.